Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Outcome
Finished, no results posted
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
7 December 2021
Ended
30 June 2026
Enrollment
121 participants
Sites
18
Primary outcomes
Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D); Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy; NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1; Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy; Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy
Sponsor type
Industry
Results posted
No
Last update
9 October 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.